ATRC

NEUTRALAnalyst

AtriCure, Inc.

2026-09-23

Price

$59.96

+1.91%

This is the 2026-09-23 snapshot — the signals and analysis for ATRC as of this single trading day.

View full ATRC research hub →

Score3.8Watchlist

Signals4/8 DNA0/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume0.8xvs 20d avg

Analysis

AtriCure (ATRC) is breaking out to 52-week highs, propelled by upward analyst revisions and a new Society of Thoracic Surgeons quality metric that expands the total addressable market for its ablation products. The stock's PERFECT_STACK and SURGE signals perfectly align with this fundamental momentum, reflecting aggressive institutional accumulation. Supported by a highly constructive RISK_ON macro regime that ignores rate risks in favor of resilient growth, the market is easily absorbing minor insider selling. This triangulation of strong technicals and fundamental tailwinds confirms a classic High-Conviction Price Discovery phase.

Fired Signals

SURGEGOLDEN CROSSMARKET LEADERPERFECT STACKWEAK FINISHEXTENSION

Key Takeaways

Actionable Thesis: ATRC is exhibiting structural leadership (+22.9% vs SPY) fueled by fundamental catalysts and analyst upgrades, making it a high-conviction momentum long.
Key Risk: Stretched valuation metrics (P/S over 5x) and recent insider selling could trigger near-term profit-taking if the broader market loses its risk-on appetite.
What to Watch: Monitor the stock's ability to hold the $60 breakout level; a failure to hold could see a retest of the $48.17 line-in-the-sand support.

← Back to 2026-09-23 View Full ATRC History →Yahoo Finance &nearr;